StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$80.00+1.06 (+1.34%)

Close on Nov 18, 2026Market cap $7.09BP/E –Yield –

CG Oncology revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

CG Oncology's revenue for the twelve months ending Sep 30, 2026 was $6.17M, up 183.6% year over year. For fiscal 2025 it was $4.04M, up 254.7% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.04M+254.7%
FY2024Dec 31, 2024$1.14M+458.3%
FY2023Dec 31, 2023$204.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.60M-3.7%
Q2 FY2026Jun 30, 2026$1.16M–
Q1 FY2026Mar 31, 2026$1.08M+1982.7%
Q4 FY2025Dec 31, 2025$2.32M+409.2%
Q3 FY2025Sep 30, 2025$1.67M+3774.4%
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$52.00K-90.2%
Q4 FY2024Dec 31, 2024$456.00K+45500.0%
Q3 FY2024Sep 30, 2024$43.00K+377.8%
Q2 FY2024Jun 30, 2024$111.00K–
Q1 FY2024Mar 31, 2024$529.00K+172.7%
Q4 FY2023Dec 31, 2023$1.00K–
Q3 FY2023Sep 30, 2023$9.00K–
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$194.00K–

More CG Oncology figures

See a number that looks wrong?